Skip to content

Assessment of the Efficacy and Safety of OROXID® Oral Solution in Patients With Oral Cavity Surgery

Assessment of the Efficacy and Safety of OROXID® Oral Solution in Patients With Oral Cavity Surgery

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06987253
Acronym
OroxSurge
Enrollment
60
Registered
2025-05-23
Start date
2025-11-06
Completion date
2026-05-31
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tooth Extrusion, Wound Healing

Keywords

Oral cavity wound, Hydrogen peroxide, Mouthwash

Brief summary

Oral tissue healing is significantly affected by the high bacterial load and constant mechanical stress within the oral cavity. To control bacterial colonization and support healing, both topical and systemic treatments-such as antibiotics and anti-inflammatory agents-are commonly recommended. In addition to pharmacological therapies, mouthwashes containing peroxide, hyaluronic acid, chitosan, or chlorhexidine are often used to maintain low levels of pathogenic bacteria. However, current recommendations for mouthwash use are primarily based on their antibacterial properties in a healthy oral environment. Evidence supporting their role in promoting wound healing, particularly after oral surgery, remains limited. OROXID® mouthwash is a medical device formulated with active oxygen (peroxide compounds). It supports the prevention and relief of inflammation in gingival and paranasal tissues through mechanical action: the release of oxygen bubbles helps cleanse tissues by removing debris. OROXID® acts locally on the mucosal microenvironment by moistening, oxygenating, and clearing away particles and dead cells. Additionally, its slightly acidic pH (between 3 and 5) helps inhibit microbial growth. The investigators hypothesize that OROXID® may reduce post-operative side effects and complications following wisdom tooth extraction and contribute to faster wound healing.

Interventions

Patients will use OROXID® forte oral solution two to three times daily for 14 days as an adjunct to standard care.

OTHERStandard of Care (SOC)

Patients will receive standard of care meaning proper tooth brushing without the use of any mouthwash or other products aimed at reducing bacteria in the oral cavity.

Sponsors

ENIKAM d.o.o.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Systemically healthy individuals aged 18 years or older. 2. Indicated for surgical removal of an erupted or unerupted tooth and/or apicoectomy. 3. Ability and willingness to comply with post-operative oral hygiene instructions. 4. Signed informed consent form prior to participation in the study.

Exclusion criteria

1. Receipt of periodontal treatment within the past 3 months. 2. Use of mouthwashes or oral gels in the past month. 3. Presence of active gingivitis around the tooth scheduled for extraction. 4. Known allergy to any ingredients of the investigational products. 5. Presence of inflammatory conditions in the oral cavity, such as lichen planus, bullous lesions, or active gingivitis. 6. Immunocompromised individuals. 7. Known allergy to penicillin or diclofenac. 8. Pregnant or breastfeeding women. 9. Smokers who consume more than 15 cigarettes per day.

Design outcomes

Primary

MeasureTime frameDescription
Modified Landry Index7 daysDifferences in the total score of the individual components of the Modified Landry Index between the active and control groups. This entails evaluating the following parameters in a comparative manner using a dichotomic score: gingival color (0 = red, 1 = pink); granulation tissue (0 = present, 1 = absent); tissue epithelialization (0 = partial/1 = complete); swelling (0 = pres- ence, 1 = absent); bleeding on palpation (0 = present, 1 = absent); sup- puration on palpation (0 = present, 1 = absent). The total score, ranging from 0 to 6, reflects the overall quality of healing, with higher scores indicating more favorable outcomes.

Secondary

MeasureTime frameDescription
Completely Healed Wounds14 daysProportion of completely healed wounds at 14 days in the active versus control group.
Mean Early Healing Index7 and 14 daysMean Early Healing Index (EHI) scores will be used to compare the groups. The EHI evaluates key clinical indicators of wound healing, including redness, swelling, bleeding, and epithelialization. Scores range from 0 to 5, with 0 representing very poor healing and 5 indicating excellent healing. Higher EHI scores correspond to more favorable healing outcomes.
Plaque Index7 and 14 daysDifferences in Plaque Index (PI) scores between the active and control groups will be evaluated using the Silness and Löe Plaque Index. This index assesses the thickness of dental plaque along the gingival margin based on the following scoring criteria: Score 0 = No plaque score; 1 = Mild plaque along the gingival margin; Score 2 =Moderate layer of plaque along gingival margin, interdental spaces free; Score 3 = Abundant plaque along the gingival margin, interdental spaces filled with plaque. Higher scores indicate poorer oral hygiene and greater plaque accumulation.
Pain ReliefIn the first 7 daysAssessment of additional analgesic use (measured in days) will be conducted to compare the active and control groups.
Infection rate7 and 14 daysIncidence of post-operative infections in each group

Countries

Slovenia

Contacts

Primary ContactDominika Tompa Majcen MPharm
dominika@enikam-oxy.com+386 40 530 663
Backup ContactDominika Tompa Majcen
dominika@enikam-oxy.com+386 40 530 663

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026